Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Peptides are not steroids: GH secretagogues work within the bodys own hormonal feedback system
This step-by-step dose increase is important because it gives the body time to adjust and may reduce stomach-related side effects
What sets retatrutide apart is not how long it lasts in your body but what it does while it is there
Real-world safety data from the FDA Adverse Event Reporting System suggests that Mounjaro may actually have lower pancreatitis risk compared to some other GLP-1 receptor agonists: Mounjaro (tirzepatide): Adjusted ROR 2.74 (suggests the reporting rate is about 2.7 times higher than would be expected if there was no association) Liraglutide (Saxenda): ROR 4.76 (suggests the reporting rate is about 4.8 times higher than expected, making it higher risk than Mounjaro) Semaglutide (Wegovy/Ozempic): ROR 2.04 (suggests the reporting rate is about 2 times higher than expected, slightly lower than Mounjaro) Dulaglutide (Trulicity): ROR 2.01 (suggests the reporting rate is about 2 times higher than expected, slightly lower than Mounjaro) While these numbers may seem complicated, they suggest that Mounjaros pancreatitis risk is comparable to or lower than that of other medications in the same class, with liraglutide showing a notably higher risk signal
Compounded formulations with higher osmolarity may cause more visible reactions
